Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia

Malin S Nilsson, MSc, Alexander Hallner, PhD, Mats Brune, MD PhD, Staffan Nilsson, PhD, Fredrik B Thorén, PhD, Anna Martner, PhD, Kristoffer Hellstrand, MD PhD

Blood (2019) 134 (Supplement_1): 1318.

https://doi.org/10.1182/blood-2019-130345

Published: 2019

Journal Articles

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

Gunnar Juliusson, Oskar Hagberg, Vladimir Lj Lazarevic, Emma Ölander, Petar Antunovic, Jörg Cammenga, Lovisa Wennström, Lars Möllgård, Mats Brune, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Åsa Rangert Derolf, Martin Höglund

Blood (2019) 134 (18): 1558–1561.

https://doi.org/10.1182/blood.2019001728

Published: 2019

Includes: Supplemental data

Journal Articles

The HLA-B −21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia

Alexander Hallner, Elin Bernson, Brwa Ali Hussein, Frida Ewald Sander, Mats Brune, Johan Aurelius, Anna Martner, Kristoffer Hellstrand, Fredrik B. Thorén

Blood (2019) 133 (13): 1479–1488.

https://doi.org/10.1182/blood-2018-09-874990

Published: 2019

Includes: Supplemental data

Journal Articles

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Mats Brune, MD PhD, Thomas L. Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Josee Hebert, MD, Martin Höglund, MD PhD, Ain Kaare, MD, Vladimir Lazarevic, MD PhD, Malin Nicklasson, MSc, Kari Remes, MD PhD, David Ritchie, MBChB, PhD FRACP, FRCPA, Mitchell Sabloff, MD, Ruth Spearing, MD, Alexandros Spyridonidis, MD PhD, Jeffrey Szer, MBBS, Per Ljungman, MD PhD

Blood (2018) 132 (Supplement 1): 205.

https://doi.org/10.1182/blood-2018-99-110260

Published: 2018

Journal Articles

Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)

Thomas L Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Tobias Gedde-Dahl, MD PhD, Vladimir Lj Lazarevic, MD PhD, Kari Remes, MD PhD, David Ritchie, MD PhD, Mitchell Sabloff, MD, Alexandros Spyridonidis, MD PhD, Per Ljungman, Mats Brune, MD

Blood (2017) 130 (Supplement 1): 4557.

https://doi.org/10.1182/blood.V130.Suppl_1.4557.4557

Published: 2017

Journal Articles

Impact of HLA-B Dimorphism in the Leader Peptide on Clinical Outcome in AML

Alexander Hallner, Msc, Elin Bernson, Msc, Brwa Ali Hussein, MD, Frida E Sander, PhD, Mats Brune, MD, Johan Aurelius, PhD, Anna Martner, PhD, Kristoffer Hellstrand, MD PhD, Fredrik B Thoren

Blood (2017) 130 (Supplement 1): 1425.

https://doi.org/10.1182/blood.V130.Suppl_1.1425.1425

Published: 2017

Journal Articles

Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study

Krista Vaht, MD, Magnus Göransson, MD PhD, Kristina Carlson, MD PhD, Cecilia Isaksson, MD, Stig Lenhoff, Anna Sandstedt, MD, Bertil Uggla, MD PhD, Per T. Ljungman, MD PhD, Mats Brune, MD PhD, Per-Ola Andersson, MD PhD

Blood (2016) 128 (22): 3905.

https://doi.org/10.1182/blood.V128.22.3905.3905

Published: 2016

Journal Articles

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Ajib Salem, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Penter Livius, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, MD, Michael Lübbert, MD, Ralph Wäsch, MD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Omid Shah, MD, Robert S. Negrin, MD, Mats Brune, MD PhD, Alexandros Spyridonidis, MD PhD, Annette Schmitt-Graeff, MD, Walter J.F.M. van der Velden, MD PhD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MD PhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Jakob R. Passweg, Joerg Halter, MD, Gérard Socié, MD PhD, Dietrich W. Beelen, Prof. Dr. MD, Christian Peschel, MD, Andreas Neubauer, Jürgen Finke, Justus Duyster, MD, Nikolas von Bubnoff, MD

Blood (2016) 128 (22): 4561.

https://doi.org/10.1182/blood.V128.22.4561.4561

Published: 2016

Journal Articles

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Blood (2013) 122 (7): 1284–1292.

https://doi.org/10.1182/blood-2013-04-495598

Published: 2013

Journal Articles

Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91 phox expression and the PARP-1/PAR pathway of apoptosis

Johan Aurelius, Fredrik B. Thorén, Ali A. Akhiani, Mats Brune, Lars Palmqvist, Markus Hansson, Kristoffer Hellstrand, Anna Martner

Blood (2012) 119 (24): 5832–5837.

https://doi.org/10.1182/blood-2011-11-391722

Published: 2012

Includes: Supplemental data

Journal Articles

Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years.

Vikas Gupta, Nicolaus Kroger, Johan Aschan, Brian Leber, Christopher Dalley, Mitchell Sabloff, Jeffrey H. Lipton, Hans Messner, Wei Xu, Mats Brune

Blood (2007) 110 (11): 1095.

https://doi.org/10.1182/blood.V110.11.1095.1095

Published: 2007

Journal Articles

Histamine Dihydrochloride Maintains Cytotoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress.

Ana I. Romero, PhD, Fredrik B. Thorén, PhD, Mats Brune, PhD, MD, Kristoffer Hellstrand, PhD, MD

Blood (2007) 110 (11): 2309.

https://doi.org/10.1182/blood.V110.11.2309.2309

Published: 2007

Journal Articles

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Mats Brune, Sylvie Castaigne, John Catalano, Kurt Gehlsen, Anthony D. Ho, Wolf-Karsten Hofmann, Donna E. Hogge, Bo Nilsson, Reuven Or, Ana I. Romero, Jacob M. Rowe, Bengt Simonsson, Ruth Spearing, Edward A. Stadtmauer, Jeff Szer, Elisabeth Wallhult, Kristoffer Hellstrand

Blood (2006) 108 (1): 88–96.

https://doi.org/10.1182/blood-2005-10-4073

Published: 2006

Includes: Supplemental data

Journal Articles

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT

Blood (2005) 106 (9): 2969–2976.

https://doi.org/10.1182/blood-2004-09-3544

Published: 2005

Journal Articles

Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

Laurent Garderet, Myriam Labopin, Norbert-Claude Gorin, Emmanuelle Polge, André Baruchel, Giovanna Meloni, Juan Ortega, Jaak Vossen, Donald Bunjes, Guy Leverger, Didier Blaise, Augustin Ferrant, Mats Brune, Eric Dore, Helmut Gadner, Felix Zintl, Isaac Yaniv, Giorgio Dini, Francesco Frassoni

Blood (2005) 105 (1): 405–409.

https://doi.org/10.1182/blood-2004-03-1103

Published: 2005

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

Journal Articles

Increased Risk for EBV-Lymphoma after Allogeneic Hsct in Adult Lymphoma Patients?A Retrospective Study of Reduced Compared to Myeloablative Conditioning.

Hans G. Hagglund, MD, PhD, Mats Brune, MD, PhD, Gunnar Oberg, MD, PhD, Hans Hagberg, MD, PhD, Niklas Theorin, MD, Mats Remberger, PhD, Eva Kimby, MD, PhD.

Blood (2004) 104 (11): 5116.

https://doi.org/10.1182/blood.V104.11.5116.5116

Published: 2004

Journal Articles

Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation

Mehmet Uzunel, Jonas Mattsson, Mats Brune, Jan-Erik Johansson, Johan Aschan, Olle Ringdén

Blood (2003) 101 (2): 469–472.

https://doi.org/10.1182/blood-2002-02-0571

Published: 2003

Journal Articles

Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine

Ulf-Henrik Mellqvist, Markus Hansson, Mats Brune, Claes Dahlgren, Svante Hermodsson, Kristoffer Hellstrand

Blood (2000) 96 (5): 1961–1968.

https://doi.org/10.1182/blood.V96.5.1961

Published: 2000

NARROW

Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

The HLA-B −21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)

Impact of HLA-B Dimorphism in the Leader Peptide on Clinical Outcome in AML

Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91 phox expression and the PARP-1/PAR pathway of apoptosis

Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years.

Histamine Dihydrochloride Maintains Cytotoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress.

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT

Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Increased Risk for EBV-Lymphoma after Allogeneic Hsct in Adult Lymphoma Patients?A Retrospective Study of Reduced Compared to Myeloablative Conditioning.

Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation

Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only